[REVISION HISTORY]

Psilocybin research and therapeutic outcomes

Updated 2 times since CLSTR started tracking revisions of this situation.

What changed

2026-08-25 10:18 UTC → 2026-08-26 05:32 UTC · added ~~removed~~

Research into psilocybin has transitioned from exploring microdosing protocols and observational links to evaluating structured, state-regulated therapeutic programs. Initial reports focused on microdosing guides, such as the Fadiman schedule, which suggest sub-perceptual doses for enhancing creativity and mood, though researchers noted that clinical evidence remains limited. Observational studies also suggested a correlation between occasional psilocybin use during alcohol consumption and fewer depressive symptoms, though causality was not proven. Subsequent findings from Oregon’s state-regulated psilocybin program provided more specific clinical data. A study published in JAMA Network Open regarding 346 adults receiving services at licensed centers between November 2024 and March 2026 showed significant declines in moderate-to-severe symptoms: depression fell from 42.2% to 16.5%, anxiety from 45.1% to 13.2%, and PTSD symptoms from 48% to 16.8%. Life satisfaction also rose from 63% to over 82% within three months. The program was described as generally safe, with serious adverse reactions occurring in approximately 1.2% of participants (four individuals) who required medical attention for behavioral reactions. Nearly 59% of participants ranked the experience among the “top ten most significant experiences of their lives.” In Australia, where psilocybin was approved for treatment-resistant depression in 2023, patient access remains low, with approximately 65 patients accessing therapy in 2025. High costs, ranging from $15,000 to $30,000 per session, remain a major barrier, though regulations requiring a psychiatrist’s presence were recently relaxed to reduce expenses. ~~Researchers continue to face challenges in gathering gold-standard~~ Recent clinical ~~evidence due to~~ research has expanded into treating addiction and eating disorders. In the ~~difficulty~~ United Kingdom, Imperial College London researchers reported that 18 out of ~~conducting double-blind placebo trials~~ 21 women with ~~hallucinogenic substances.~~ anorexia nervosa showed a reduction in eating disorder scores following six weeks of psilocybin administration paired with intensive psychotherapy; nearly half maintained scores comparable to those without eating disorders after one year.

Versions

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.